ANAHEIM, Calif., Oct. 15, 2018 /PRNewswire-PRWeb/ -- Golden Future Expos Inc. (GFE) is proud to announce that Flexion
As this year's Presenting Sponsor, Flexion will offer attendees information about ZILRETTA, the first and only FDA-approved treatment for osteoarthritis knee pain that uses extended-release microsphere technology.
Osteoarthritis (OA) is a chronic and degenerative joint disease that affects more than 30 million Americans. In 2016, more than 15 million Americans were diagnosed with OA of the knee, and the average age of people diagnosed with knee OA has fallen by 16 years, from 72 in the 1990s to 56 in the 2010s. The prevalence of OA is expected to continue to increase as a result of aging, obesity, and sports injuries.
"We believe ZILRETTA can benefit millions of Americans suffering from osteoarthritis of the knee," said Dan Deardorf, Senior Vice President, Commercial Operations at Flexion. "By joining the Golden Future Expo this year as the Presenting Sponsor, we hope to help people living with knee osteoarthritis reimagine what a season with less knee pain could mean for them."
In addition to learning more about ZILRETTA, Expo attendees will be able to participate in a variety of fun and engaging activities at the ZILRETTA booth. They will have the opportunity to challenge each other to virtual sports games, pick up giveaways, and hear first-hand from people who have tried ZILRETTA for their osteoarthritis knee pain.
For more information about ZILRETTA and Flexion Therapeutics, visit http://www.ZILRETTA.com.
For more information on The Golden Future 50+ Senior Expo Series, please visit the event website at http://www.goldenfutureseniorexpo.com or call 805-716-3303.
Indication and Important Risk Information
What is ZILRETTA? ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is an extended-release corticosteroid approved to manage osteoarthritis knee pain. It is not intended for repeat use.
Who should not receive ZILRETTA? You should not receive a ZILRETTA injection if you are allergic to corticosteroids, triamcinolone acetonide, or any other component of the product.
What possible side effects of corticosteroids could occur with ZILRETTA?
What are the most common side effects of receiving a ZILRETTA injection? In multiple clinical trials, the most common side effects seen in people taking ZILRETTA were joint pain, headache, joint swelling, back pain, sore throat and runny nose, upper respiratory tract infection, and bruising.
What should you tell your doctor BEFORE receiving a ZILRETTA injection? Tell your doctor about all of the medications you are taking (including both prescription and over-the-counter medicines) and about any medical conditions, especially if you have high blood pressure, heart disease, ulcers, diverticulitis or other gastrointestinal disorders, kidney problems, diabetes, glaucoma, behavior or mood disorders, and/or infections.
What should you tell your doctor AFTER receiving a ZILRETTA injection? Contact your doctor if you develop a fever or other signs of infection, have an increase in pain along with swelling of the injected knee, restriction of joint motion, or a general feeling of discomfort. Contact your doctor immediately if you are exposed to chicken pox or measles, or for any new or worsening changes in behavior or mood.
These are not all of the possible side effects with ZILRETTA or corticosteroid medications. Please see the full Prescribing Information at http://www.ZILRETTALabel.com/PI.pdf. Always contact your doctor if you have questions or experience any side effects.
You are encouraged to report side effects to the FDA: Call 1-800-FDA-1088 (332-1088), or visit http://www.fda.gov/medwatch. You may also report side effects to Flexion at 1-844-FLEXION (353-9466).
About ZILRETTA On October 6, 2017, ZILRETTA was approved by the U.S. FDA as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis-related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide — a commonly administered, short-acting corticosteroid — with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief over 12 weeks.
About Flexion TherapeuticsFlexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017.
SOURCE Golden Future Expos Inc.
Subscribe to our Free Newsletters!